Bromodomain And Extra Terminal Domain (bet) Inhibitors - Cancer Science

Relevant Publications

BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436.

Issue Release: 2024

RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma.

Issue Release: 2024

Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.

Issue Release: 2024

Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.

Issue Release: 2024

Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia.

Issue Release: 2024

Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.

Issue Release: 2024

BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.

Issue Release: 2024

BRD4: an effective target for organ fibrosis.

Issue Release: 2024

Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines.

Issue Release: 2024

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells.

Issue Release: 2024

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.

Issue Release: 2024

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.

Issue Release: 2024

A Novel BD2-Selective Inhibitor of BRDs Mitigates ROS Production and OA Pathogenesis.

Issue Release: 2024

Development and Evaluation of [C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging.

Issue Release: 2024

Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.

Issue Release: 2024

Liver-targeting chimeras as a potential modality for the treatment of liver diseases.

Issue Release: 2024

The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer.

Issue Release: 2024

Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy.

Issue Release: 2024

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8.

Issue Release: 2024

BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics